References
- [1] Supreme Court of Canada, AstraZeneca Canada Inc. v. Apotex Inc, 30 June 2017, 2017 SCC 36 European Court of Human Rights (ECHR)
- [2] Anheuser-Busch v. Portugal, Judgment of 11 October 2005 (Court, 2nd section), Application n° 73049/01
- [3] Anheuser-Busch v. Portugal, Judgment of 11 January 2007, (Court, Grand Chamber), Application n° 73049/01
- [4] Global Trading Resource Corp. and Others v. Ukraine (ICSID Case n°ARB/09/11), Award declining jurisdiction, 1st December 2010
- [5] Grand River Enterprises Six Nations Ltd. v. United States, Ad Hoc Award declining jurisdiction, 12 January 2011
- [6] Metalclad v. Mexico (ICSID Case n°ARB(AF)/97/1), Award, 30 August 2000
- [7] Saluka Investmens BV v. Czech Republic, Ad Hoc Partial Award, of 17 March 2006 Interstate Arbitration
- [8] Italy v Cuba, procedure based on the Italy-Cuba BIT, Ad hoc Award, 15 January 2008
- [9] Affaki G. (2004), ‘Le banquier et l’arbitre’, Banque & Droit, n° 93
- [10] Boie B. (2010), The Protection of Intellectual Property Rights Through Bilateral Investment Treaties: Is There a TRIPS-Plus Dimension?, 4 NCCR Trade Regulation, Working Paper No. 2010/19
- [11] Dubuisson F. (2017), ‘Investissement étranger et droits de propriété intellectuelle’, in Le droit des investissements internationaux : perspectives croisées, Sabrina Robert-Cuendet dir., Bruylant
- [12] Guerriaud M., Jourdain-Fortier C., Moine-Dupuis I. (dir.) (2020), Le droit des affaires pharmaceutiques; vers une caractérisation d’une lex pharmaceutica?, LexisNexis
- [13] Kahn A.-E. (2007), ‘Les licences obligatoires’, in Le médicament et la personne, aspects de droit international, I. Moine-Dupuis dir. LexisNexis, travaux du CREDIMI Vol. 28
- [14] Liberti L. (2010), Intellectual Property Rights in International Investment Agreements: An Overview, OECD Working Papers on Int’l Inv. 2010/01
- [15] Manciaux S. (2010), ‘Actualité de la notion d’investissement international’, in La procédure arbitrale relative aux investissements internationaux : aspects récents, C. Leben dir., Anthémis/LGDJ
- [16] Manciaux S. (2019), ‘The Full Protection and Security Standard in Investment Law: A Specific Obligation?’, in International Investment Law and the Law of Armed Conflict, Katia Fach Gomez, Anastasios Gourgourinis and Catharine Titi eds, European Yearbook of International Economic Law, Springer ed.
- [17] Schwarz F. and Berajano S. (2014), ‘Arbitration: Big Pharma, Big Player’, www.cdr-news.com, Nov.-Dec
- [18] Sell S. K. (2007), “TRIPS-Plus Free Trade Agreements and Access to Medicines”, 28 Liverpool L.R., 41
- [19] Titi C. (2014), The Right to Regulate in International Investment Law, Nomos Verlagsgesellschaft ed.
- [20] Tran J., “Vietnam 2020: A Pharmaceutical Industry with Major Opportunities for Multi-National Companies”. Retrieved from https://www.linkedin.com/pulse/vietnam-2020-pharmaceutical-industry-major-companies-james-tran/ [accessed on 15 April 2021]
- [21] Ugarte R., Stirnimann F. et Bentolila D. (2013), ‘Pharmaceuticals: a new frontier in investment treaty arbitration’, Global Arbitration Review, 6 September 2013. Retrieved from www.globalarbitrationreview.com [accessed on 15 April 2021]
- [22] Vadi V. S. (2015), ‘Towards a new dialectics: pharmaceutical patents, public health and foreign direct investments’, 5 NYU Journal of Intellectual Property and Entertainement Law, No. 1
- [23] Vietnam Investment Review (2018),“Vietnam’s six large-scale foreign pharmaceutical firms”, 1 March 2018. Retrieved from https://vir.com.vn/vietnams-six-large-scale-foreign-pharmaceutical-firms-56624.html [accessed on 15 April 2021]